Late Breaking Abstract - Oral corticosteroid (OCS) risk predictor for Type II Diabetes in asthma
B. Stanley (One Shenton, Singapore), A. Menzies-Gow (London, United Kingdom), A. Bourdin (Montpellier, France), G. Canonica (Milan, Italy), M. Gurnell (Cambridge, United Kingdom), H. Reddel (Glebe, Australia), L. Heaney (Belfast, United Kingdom), V. Carter (One Shenton, Singapore), J. Chapaneri (Cambridge, United Kingdom), T. Tran (Gaithersburg, United States), E. Maslova (Cambridge, United Kingdom), D. Price (One Shenton, Singapore)
Source: International Congress 2022 – Chronic cough: management and impact on quality of life
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
B. Stanley (One Shenton, Singapore), A. Menzies-Gow (London, United Kingdom), A. Bourdin (Montpellier, France), G. Canonica (Milan, Italy), M. Gurnell (Cambridge, United Kingdom), H. Reddel (Glebe, Australia), L. Heaney (Belfast, United Kingdom), V. Carter (One Shenton, Singapore), J. Chapaneri (Cambridge, United Kingdom), T. Tran (Gaithersburg, United States), E. Maslova (Cambridge, United Kingdom), D. Price (One Shenton, Singapore). Late Breaking Abstract - Oral corticosteroid (OCS) risk predictor for Type II Diabetes in asthma. 914
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|